A team from the University of Bath, University of Oxford, and Johns Hopkins is deploying organ-on-chip technology to investigate the biological link between diabetes and dementia. This approach aims to uncover how these two conditions interact at a cellular level, potentially leading to new combination therapies for patients suffering from either or both diseases.
The research leverages microfluidic devices that simulate human organ function, allowing scientists to observe disease mechanisms in real-time. By modeling the metabolic and vascular changes common to both diabetes and dementia, the team hopes to identify shared pathological pathways that could be targeted by novel drugs. The method is designed to be more predictive than traditional animal or cell culture models.
This work remains at an early, proof-of-concept stage with no clinical trial dates announced. The researchers are focused on validating the chip models against known clinical data before advancing toward therapeutic candidate identification. Regulatory pathways for organ-on-chip-derived insights are still being established, though the FDA has shown increasing willingness to consider such data in drug development.
The project draws on expertise from three leading institutions, combining Bath's bioengineering, Oxford's clinical neurology, and Johns Hopkins' endocrinology. While no investor funding has been disclosed, the approach could attract interest from pharmaceutical companies seeking to de-risk diabetes and dementia drug programs. The global dementia treatment market is expected to grow significantly as populations age.
If successful, this method could accelerate drug development for millions affected by both conditions. However, translating organ-on-chip findings into effective human therapies remains a significant challenge, as these models cannot fully replicate the complexity of whole-body metabolism and neurodegeneration.